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Abstract 
Excessive erythrocytosis results in severely increased blood viscosity that may 
compromise the vascular endothelium. Using our transgenic mouse model of excessive 
erythrocytosis we previously showed that despite altered brain endothelial cell 
morphology and an activated vasculature, brain vascular integrity was largely maintained 
up to 4-5 months of age. We now present data showing that persistent long-term damage 
of the vascular wall during the later stages of adulthood (9-10 months) results in a chronic 
detrimental inflammatory phenotype and increased vessel permeability that likely 
contributes to the reduced life span of our erythropoietin overexpressing transgenic 
mouse. In aged transgenic animals inflammatory cells were detected in brain tissue and 
elevated RNA and protein levels of inflammatory markers such as IL-6 and TNFα were 
observed in both brain tissue and blood plasma. Additionally, increased expression of p53 
and other pro-apoptotic markers, as well as decreased Bcl-xL expression in the brain 
vasculature, indicated ongoing cell death within the vascular compartment. Finally, 
abnormally elevated vascular permeability in all organs was detected in correlation with 
decreased expression of the tight junction protein occludin and the adherens junction 
protein β-catenin in brain. Thus chronic erythrocytosis results in sustained activation of 
inflammatory pathways, vascular dysfunction and blood-brain barrier disruption.  
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1. Introduction 
Adequate oxygen delivery is crucially important for brain function because of its low 
capacity for anaerobic metabolism. The hematopoietic growth factor erythropoietin (Epo) 
circulates in plasma and controls the oxygen carrying capacity of the blood (Fisher, 2003; 
Velly et al.). Epo is produced primarily in the adult kidney and fetal liver and was 
originally believed to play a role restricted to stimulation of early erythroid precursors 
and differentiation of the erythroid lineage. In addition to its well known role in 
erythropoiesis however a diverse array of cells have now been identified that produce 
Epo and/or express the Epo receptor including endothelial cells, smooth muscle cells and 
cells of the central nervous system (Digicaylioglu et al., 1995; Masuda et al., 1994). In 
vitro Epo has been shown to regulate a variety of neural functions such as calcium flux 
(Korbel et al., 2004) neurotransmitter synthesis and cell survival (Velly et al., 2010; 
Vogel et al., 2003). Furthermore Epo has neurotrophic effects (Chen et al., 2007; Grimm 
et al., 2002; Junk et al., 2002), can induce an angiogenic phenotype in cultured 
endothelial cells, is a potent angiogenic factor in vivo (Ribatti et al., 2003) and enhances 
ventilation in hypoxic conditions (Soliz et al., 2005).  
Clinically, due to its role in erythrocytosis, lack of Epo leads to anemia with fatigue and 
cellular hypoxia. Thus recombinant human Epo (rhEpo) is a frequently used therapeutic 
to increase red blood cell number and improve oxygen delivery. Excessive erythrocytosis 
however results in abnormally high blood viscosity and is often associated with severe 
clinical complications such as hypertension and thromboembolism (Bertinieri et al., 
1998; Ruschitzka et al., 2000). Notably the effects of elevated Epo levels, and thus 
resultant high hematocrit, on blood vessel function and structure per se has not been fully 
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investigated. The integrity of blood vessel wall structure is essential to facilitate efficient 
blood transport/perfusion and the efficient oxygenation of all tissue beds and organs. 
Vascular remodelling to suit local tissue needs may therefore be an important adaptation 
to excessive erythrocytosis. Indeed endothelial cells that are in direct contact with high 
blood viscosity, may be altered and undergo changes in permeability and structure. Such 
alterations/modifications may compromise blood-brain barrier integrity and disturb 
neuronal homeostasis in the brain. 
To study adaptive mechanisms to excessive erythrocytosis we have generated a mouse 
model (designated tg6) that constitutively over expresses human Epo in an oxygen-
independent manner. Generation and characterization of this line showed these mice have 
a hematocrit of 0.8-0.9 after the first 8-9 weeks without increased blood pressure or 
altered cardiac output as well as reduced exercise performance and a significantly 
reduced life span of 9-12 months (Heinicke et al., 2006; Ogunshola et al., 2006; 
Ruschitzka et al., 2000; Vogel et al., 2003; Wagner et al., 2001). Interestingly both NO 
mediated relaxation and circulating NO levels are markedly elevated leading to increased 
vasodilation and protection from cardiac complications (Ruschitzka et al., 2000). 
Using this transgenic model we previously investigated the direct effect of Epo and the 
impact of excessive erythrocytosis on angiogenesis, blood vessel wall structure and 
integrity in adult mice of 4-5 months of age (Ogunshola et al., 2006). We observed 
significant activation of the brain vascular endothelium however, surprisingly, blood-
brain barrier permeability remained unaffected (Ogunshola et al., 2006). Thus 
compensatory mechanisms seemed to enable normal vascular function. This follow up 
work investigates the long term effects of chronic erythrocytosis in aged animals of 9-10 
months. Our data shows that both inflammatory and cell death pathways are strongly 
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stimulated in the vascular compartment and likely cause wide-spread damage to the 
vascular endothelia. Accordingly, all organs display a significant increase in vascular 
permeability. Thus during the aging process sustained chronic excessive erythrocytosis 
activates multiple mechanisms that reduce organ function and ultimately contribute to 
premature death. 
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 2. Results 
2.1 Endothelial activation markers remain upregulated during aging in mice 
exhibiting excessive erythrocytosis 
Previously we have shown that chronic excessive erythrocytosis results in activation of 
the brain vasculature in adult tg6 mice. We now investigated the activation status of the 
brain vasculature in aged tg6 mice of 9-10 months of age using immunohistochemistry 
for VCAM-1. Tg6 endothelium was found to be strongly VCAM-1 positive indicating 
continuous activation of the vascular bed (Fig. 1A) compared to wt animals. Inserts show 
high magnification of the vascular structures that stain positive for VCAM-1. Western 
blotting and quantification confirmed this result showing a very strong expression of 
VCAM-1 in brain lysates of tg6 but not wt animals. Notably, ICAM-1 protein levels were 
also upregulated (Fig. 1B). 
 
2.2 Inflammatory mediators and cytokines are elevated in aged tg6 mice 
To further ascertain the impact of chronic vascular activation we performed quantitative 
polymerase chain reaction (qPCR) analysis of mRNA from tg6 and wt brain tissue. We 
observed a 2-3 fold increase in both IL-1β and TNFα as well as modest but significantly 
elevated levels of VCAM-1 and iNOS (Fig. 2A). Thus expression of inflammatory 
cytokines is significantly increased in the transgenic animals. In blood plasma we also 
observed that circulating levels of IL-6 were more than doubled compared to wt mice 
(Fig. 2B), further indicating that inflammatory pathways are chronically induced in tg6 
animals. We subsequently identified the main source of the systemically increased IL-6 
levels as being the kidney, liver and spleen - organs that are known to undergo significant 
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degeneration during the aging of these mice (Fig. 2C, (Heinicke et al., 2006)). Although 
brain and heart tissue did not express significantly increased levels of IL-6 the 
systemically increased IL-6 suggested the possibility of increased infiltration of 
inflammatory cells within many tissues including the brain parenchyma. Accordingly, we 
detected a limited number of inflammatory cells usually absent from the normal brain in 
aged tg6 mice (figure 2D). Indicative of an impairment of the blood-brain barrier, the 
infiltrating macrophages (CD11b+) and T-cells (CD4+, data not shown) were frequently 
detected in or around blood vessels in the transgenic brain.  
 
2.3 Increased cell death in tg6 brain vasculature 
The inflammatory phenotype observed in aged tg6 mice suggested a significant 
detrimental effect on the vascular endothelial cells. Accordingly we observed reduced 
expression of Bcl-2 mRNA (Fig. 2A) and increased protein expression of pro-apoptotic 
proteins such as p53, Bax and Bnip3 in tg6 brain tissue compared to wt (Fig. 3A). 
Concomitantly, reduced levels of the anti-apoptotic protein Bcl-xL were also noted in tg6 
brain lysates (Fig. 3B) further highlighting a significant increase in cell death pathways in 
these animals. Immunohistochemistry demonstrated that in the brain p53 is indeed mainly 
localized to CD31+ve blood vessels (Fig. 3C and D) and is elevated in tg6 mice 
underlining the reduced survival of cells within the vascular bed. Interestingly plasma 
levels of VEGF, a growth factor known to be very important for survival of many cells in 
the brain and other organs, was also observed to be significantly down-regulated (Fig. 
3E). 
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2.4 Vascular integrity is compromised in aged tg6 mice 
To observe alterations in vascular integrity in aging animals we performed Evans Blue 
extravasation assays on aged wt and tg6 mice. Unlike the results from younger animals in 
our previous studies (Ogunshola et al., 2006), all aged tg6 mouse organs had significantly 
increased leakage of Evans Blue into the tissue parenchyma compared to wt littermates 
(Fig. 4A). Notably, although the greatest flux was observed in the kidney, the normally 
highly impermeable brain vasculature also revealed significant leakage compared to wt 
animals. This data also correlated with Western blotting data from brain lysates showing 
a distinct decrease in expression of the tight junction protein occludin (Fig. 4B and C). 
The expression of β-catenin, a protein involved in maintenance of endothelial adherens 
junctions, was also significantly downregulated (Fig. 4B and C). Surprisingly, levels of 
claudin-5 and the adaptor protein ZO-1, other components of tight junctions, remained 
unaffected (Fig. 4B and C).  
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3. Discussion 
Despite hematocrit values of 0.8-0.9 and an activated endothelium, blood-brain barrier 
permeability in 4-5 month old tg6 mice remained unchanged compared to wt animals 
(Ogunshola et al., 2006). Thus it appeared that the microvascular circulation is able to 
adapt and withstand the adverse effects of excessive erythrocytosis. However, we 
considered that sustained high levels of NO and chronic high blood viscosity observed in 
tg6 animals could eventually cause permanent damage to the vessel walls facilitating 
increased susceptibility to leakage over time. This current study supports this hypothesis 
and confirms that during the aging process sustained activation of inflammatory and 
stress response pathways culminate in elevated levels of inflammatory cytokines and 
compromised cell viability with pathological consequences. As a result permeability of 
all vasculature including the blood-brain barrier increased significantly in tg6 animals 
aged 9-12 months. 
Vascular endothelial cells are constantly subjected to shear stress imposed on them by 
blood flow. Normal physiological shear stress is vasculoprotective and fosters quiescence 
of the endothelium and vascular wall. Indeed recent work suggests that shear stress may 
be the most critical factor affecting gene expression in endothelial cells and during 
inflammation. Data from in vitro (Stone et al., 2003; Walsh et al.; Warabi et al., 2004) 
and in vivo (Xu et al., 2004; Yamawaki et al., 2003) studies indicate that low or low 
oscillating endothelial shear stress upregulates molecular and vascular responses that may 
be instrumental to progression of vascular-related diseases. Excessive erythrocytosis 
compromises vascular homeostasis as a result of significantly increased hematocrit and 
decreased plasma levels (Neunteufl et al., 2001). We have previously shown that NO-
mediated vasodilatation and increased blood viscosity are two ways by which tg6 mice 
adapt to the extremely high hematocrit levels (Vogel et al., 2003). However elevated 
blood viscosity significantly reduces blood velocity causing a concomitant lowering of 
shear stress to levels that are probably detrimental in the long term. On the other hand 
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significantly increased red blood cell content may indicate increased oxygen delivery. 
Interestingly, it was recently demonstrated that although blood viscosity is about four 
times higher in tg6, oxygen delivery is identical with wt mice again suggesting vascular 
compensatory mechanisms exist (Frietsch et al., 2007). The mechanisms underpinning 
this compensation are still largely unclear.  
Progressive blood-brain barrier breakdown is associated with diverse CNS inflammatory 
conditions. Inflammation is thought to be important in the development and/or 
progression of vascular disease and is particularly associated with alterations in the 
expression of vascular and platelet adhesion molecules, levels of coagulation factors and 
activity of oxidants and anti-oxidants (Ross, 1999) such as observed in our mouse model. 
That excessive erythrocytosis results in a state of chronic and/or recurrent inflammation 
and endothelial dysfunction correlates with results from clinical studies of polycythemia 
vera patients who also exhibit endothelial dysfunction and perturbation that may 
predispose them to arterial disease (Falanga et al., 2000; Neunteufl et al., 2001). Together 
these observations suggest that endothelial damage is indeed associated with 
polycythemia vera.  
Current evidence advocates that Epo protects many cell types against different injuries 
(reviewed in (Velly et al.; Vogel and Gassmann)). Regarding the vasculature Epo has 
been shown to increase endothelial cell survival during exposure to prolonged hypoxia in 
vitro (Chong et al., 2002) and prevent BLOOD-BRAIN BARRIER permeability by 
restoring junction protein localisation in vivo (Li et al., 2007; Martinez-Estrada et al., 
2003). It has also been shown by other groups that Epo can directly interact with and 
reduce the number of leukocytes, and the inflammatory response as a whole, in both 
kidney failure patients and mouse model systems (Shurtz-Swirski et al., 2002). Thus 
current literature suggests that a negative effect of Epo on the vasculature is very unlikely 
although at present this possibility cannot be totally ruled out. We hypothesize however 
that the inflammatory state and increased cell death markers in tg6 endothelium are not 
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directly related to elevated Epo levels but rather due to the detrimental effect of chronic 
exposure of vessels to high blood viscosity and circulating immune cells. For example, 
high blood viscosity and subsequently reduced blood velocity may increase interactions 
of endothelial cells with leukocytes. Indeed tg6 mice have increased leukocyte plasma 
levels (Wiessner et al., 2001) and we also observed inflammatory leukocytes, including 
CD11b+ and CD4+ cells within the brain parenchyma. In healthy systemic conditions 
these cells are absent from the immune-privileged CNS emphasizing partial impairment 
of the blood-brain barrier in tg6 mice. The detection of IL-6 in blood plasma and 
increased expression of TNFα and IL-1β only underline the degree of ongoing 
inflammation within the brain and various tissues. The major source of the increased 
systemic IL-6 levels was identified to be the kidney, liver and spleen. These organs have 
already been shown to undergo significant degeneration in this mouse model and 
significantly contribute to reduced life span of the animal (Heinicke et al., 2006; 
Ogunshola et al., 2006; Ruschitzka et al., 2000; Vogel et al., 2003; Wagner et al., 2001). 
In addition a functionally disturbed endothelium was already detected in these organs in 
animals at 4-5 months and in the current study using aged mice increased permeability 
was observed in all organs including brain. Although we detected only moderate 
increases in pro-inflammatory cytokine levels, the long term effects of chronic 
endothelial activation combined with low-level production of pro-inflammatory cytokines 
likely culminates in reduced vascular integrity with detrimental consequences. Indeed 
inflammatory mediators such as IL-1β, TNFα and IL-6 have been shown to have a 
prominent role in blood-brain barrier disruption (Abbott, 2000; Argaw et al., 2006). 
Though the mechanisms by which they act remain largely unclear, it has been suggested 
that IL-1β affects paracellular permeability while TNFα increases transcellular 
permeability (Abbott, 2000). Furthermore, similar to activation molecules such as ICAM-
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1 and VCAM-1, they can act directly or indirectly to attract leukocyte infiltration 
(Alvarez and Teale, 2006; Kevil et al., 2004). Such progressive inflammatory vascular 
disruption would therefore be associated with an endothelial pro-inflammatory 
phenotype, junctional complex remodeling and infiltration of leukocytes - all the 
parameters clearly noted in our study.  
Epo-mediated protection against apoptosis was shown to upregulate Bcl-xL in cultured 
neurons (Wen et al., 2002), as well as increase Bcl-2 (Wei et al., 2006) and decrease Bax 
expression (Kumral et al., 2006) in vivo. In contrast we detected a significant increase in 
expression of pro-apoptotic proteins and a concomitant decrease in survival proteins in 
tg6 brain tissue and lysates. Clearly vascular endothelial cell apoptosis would exacerbate 
barrier dysfunction and accordingly increase vascular permeability as was observed in all 
organs. Indeed even small changes in brain integrity facilitate the influx of leukocytes 
and other circulating substances that can have enormous detrimental effects on neuronal 
function. Thus loss of vascular integrity in tg6 brain, although moderate, highlights that 
the normally highly impermeable blood-brain barrier has been compromised with likely 
severe consequences. We conclude that Epo-dependent and -independent protective 
mechanisms cannot be maintained ad infinitum during the aging process but are 
overwhelmed by the progressively activated endothelium and continuous inflammatory 
state. Thus the morphological brain endothelial changes we observed in younger animals 
(Ogunshola et al., 2006) represent early signs of a gradual but persistent chronic 
endothelial disturbance prior to complete breakdown with fatal consequences. The 
scheme in figure 5 indicates the observed mechanisms that may contribute to vascular 
compromise.  
Overall this study shows that as a result of chronic excessive erythrocytosis significant 
vascular changes occur in the brain endothelium, and also in other organs during aging. 
After a period of months the cumulative effect of continued inflammation and pro-
apoptotic signaling seem to dominate. As this mouse line has a significantly reduced life 
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span we conclude that these alterations substantially contribute to the premature death of 
the animal. We propose this animal model to study different stages of endothelial 
dysfunction and vascular changes that could play a central role in the development and 
progression of chronic mountain sickness, excessive erythrocytosis and other vascular-
related diseases that cause/culminate in high hematocrit levels or are associated with 
endothelial activation. 
 
 
4. Experimental procedures 
All experiments were performed in accordance with Swiss animal protection laws and 
Zürich University institutional guidelines. The transgenic mouse line was generated by 
pronuclear injection of the full length human Epo cDNA driven by the human platelet-
derived growth factor (PDGF) B-chain promoter and has been previously described 
(Ruschitzka et al., 2000). The resulting mouse line TgN(PDGFBEPO)321ZbZ (termed 
tg6) showed increased plasma and brain levels of Epo (Wiessner et al., 2001) and was 
bred by mating hemizygous males to wild type (wt) C57BL/6 females. Half the offspring 
were hemizygous for the transgene and the other half were wt and served as controls. 
Brain tissue from male mice 9-12 months of age were used in all experiments. Of note, 
similar data was also obtained using female animals. 
 
4.1 Evans blue permeability assay 
Evans blue dye extravasation was used to assess vascular permeability. A 1% solution of 
Evans blue dye was injected intravenously into mice via the tail vein at a concentration of 
2µg/g mouse weight. The dye was allowed to circulate for 4 hours before the animals 
were anaesthetised intraperitonally with ketamine/xylazine and then perfused 
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intracardially with ice cold PBS. After 15 minutes slow perfusion, the organs were 
dissected and the dye retained in the tissue parenchyma extracted with formamide at a 
concentration of 5µl/mg weight organ for 72 hours at room temperature. Absorbance was 
then measured at 620nm. Additional experiments were also performed allowing the 
Evans blue to circulate for only 45 minutes before anaethesis and perfusion. Results 
obtained were consistent using both methods and no significant differences were 
observed between male and female mice. 
 
4.2 Quantitative polymerase chain reaction (qPCR) 
RNA from mouse brain was extracted by homogenisation in TRIzol (Invitrogen) 
according to the manufacturer’s instructions. RNA was reverse-transcribed using random 
hexamers and AMV reverse transcriptase (Promega). The cDNA equivalent to 50 ng of 
total RNA was PCR-amplified in an ABI PRISM 7700 detection system (PE-Applied 
Biosystems) using TaqMan Universal PCR Master Mix (Applied Biosystems) and 
quantified using the 2-∆CT method using 18s rRNA as a housekeeping gene. Relative 
RNA levels are expressed as x-fold variations compared to control. Primers and probes 
for Taqman analysis for IL-1β, TNFα, and iNOS were purchased from Applied 
Biosystems. Primers and probes for Bcl-2 and VCAM-1 were purchased from 
Microsynth, Switzerland. 
 
4.3 ELISA  
Quantitation of VEGF and IL-6 were performed using ELISA kits according to 
manufacturers instructions (R&D Systems GmbH, Germany). Optical density was 
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measured using a microplate reader (Multiskan RC; Thermo Labsystems, Finnland) at 
450nm with wavelength correction at 570nm. 
 
4.4 Western blotting 
Experiments were carried out on brain lysates from transgenic and littermate controls. 
Tissue was homogenised in lysis buffer by hand using a sterile dounce homogeniser. 
Samples were then centrifuged at 13,000 rpm at 4°C for 10 minutes, supernatant 
extracted and stored at –20°C. 50µg of protein were run on a 10% SDS PAGE, 
transferred to a nitrocellulose membrane, blocked in 5% non-fat milk and then incubated 
with primary antibodies overnight at 4°C or 2 hours at room temperature. Membranes 
were washed with either TBS or PBS containing 0.05% tween and then incubated for 1 
hour with a horseradish peroxidase-conjugated secondary antibody. Chemiluminescent 
detection was carried out and the membrane exposed to Kodak autoradiography film. 
Normalisation was performed by reprobing filters with β-actin (1:5000, Sigma, Saint 
Louis, USA). 
 
4.5 Antibodies 
The following antibodies were used in this study; anti-occludin, anti-ZO-1, anti-Claudin-
5 (1:1000, Zymed, San Francisco, USA), anti-β-catenin, anti-Bcl-xL (both 1:1000, BD 
transduction Labs), anti-ICAM-1, anti-VCAM-1 (intercellular and vascular cell adhesion 
molecule-1; both 1:50, Santa Cruz Biotechnology, Santa Cruz, USA) p53, Bax (1:50, 
Millipore), Bnip3 (1:500, Abcam). 
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4.6 Immunohistochemistry 
Mouse brains were dissected and immediately frozen in liquid nitrogen. 10µM frozen 
sections were cut using a cryostat. Sections were fixed with 4% paraformaldehyde in PBS 
(pH 7.4) for 5min at room temperature then permeabilised in 0.1%Triton X-100 for 2min 
and blocked with 4% normal goat serum. Sections were then incubated with primary 
antibodies anti-p53 (1:1000, Santa Cruz, CA), anti-VCAM-1 (C8,1:500, Santa Cruz, CA) 
or anti-CD11b overnight at 4°C. Secondary antibodies (AlexaFluor 488 and CY5; 
Molecular Probes, Leiden, Netherlands) were then applied for 2 hours at room 
temperature followed by counterstaining with DAPI.  
 
4.7 Statistical analysis 
Graphic and statistical analyses were performed using Microsoft excel and Prism 
software. Western blot data was quantified using NIH Image J software. Data are 
presented as mean ± standard deviation (S.D). Statistical significance (P< 0.05%) of the 
obtained data was calculated using two-tailed unpaired t-test. 
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7. Figure legends 
Figure 1: Persistent endothelial cell activation in aged tg mice 
A) Fluorescent microscopy shows expression of VCAM-1 is localized to vascular 
structures within cortical brain sections and significantly increased in tg6 compared to wt 
control mice. Scale bar = 100µM. B) Western blotting and quantification of tissue 
homogenates from tg6 and wt brain show VCAM-1 and ICAM-1 are significantly 
upregulated in the transgenic mice. β-actin was used as a loading control. All samples for 
ICAM-1 were run on the same blot however the image was cropped due to redundancy as 
indicated.  
 
Figure 2: Inflammatory pathways are strongly induced in tg6 mouse brain 
A) Quantitative PCR of various inflammatory cytokines, iNOS, VCAM-1 and Bcl-2 
using mRNA isolated from tg6 and wt brain. Bars represent mean ± SEM. *P<0.05, 
**P<0.01 versus wt control; n=4. B) IL-6 levels in blood plasma were measured by 
ELISA. A significant increase in systemic IL-6 levels was detected in tg6 plasma 
compared to wt littermates (**=p<0.005; n=5). C) Levels of IL-6 are significantly 
elevated in major organs namely kidney, liver and spleen but not heart or brain. D) 
Immunohistochemistry analysis revealed the presence of CD11b-+ve cells in the brain 
parenchyma of tg6 mice. No infiltrating cells were detected in wt mice (data not shown). 
Scale bar = 50µM. 
 
Figure 3: Cell death pathways are activated in tg6 brain 
Western blotting and quantification of brain protein lysates reveal that in tg6 animals A) 
expression of pro-apoptotic proteins are strongly induced compared to wt controls. B) In 
contrast, expression of the anti-apoptotic protein Bcl-xL is reduced in tg6. β-actin was 
used as a loading control. For each protein all samples were run on the same blot however 
the indicated images were cropped due to redundancy. C) Immunohistochemistry 
suggests that p53 (green) is localized mainly to vascular structures within the brain. Scale 
bar = 100µM. D) Confirmation of p53 expression by vascular cells by performing double 
staining with CD31. Scale bar = 50µM. Note increased intensity of stain in tg6 vessels. E) 
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Expression of VEGF, an important cytoprotective growth factor, was also down regulated 
in tg6 brain. (**=p<0.005; n=4). 
 
Figure 4: Vascular permeability is increased in aged tg animals 
A) Extravasation of Evans blue dye into tissue parenchyma was measured in organs of 
tg6 and wt mice. Significantly increased permeability was observed in all tg6 organs 
compared to control animals (*=p>0.05, **=p<0.005; n=12). B) Protein levels of the 
tight junction protein occludin are down regulated in tg6 brain lysates but in contrast 
claudin-5 levels remain unaffected. Tg6 mice also revealed significantly decreased β-
catenin expression whereas ZO-1 and P-gp were unaffected compared to wt littermates. 
β-actin was used as a loading control. C) Quantification of all Western blots is shown. 
For each protein, all samples were run on the same blot however indicated images were 
cropped due to redundancy.  
 
Figure 5: Schematic illustration of parameters involved in increased vascular 
permeability and blood-brain barrier breakdown in tg6 mice. We suggest that 
prolonged excessive erythrocytosis leads to increased expression of inflammatory 
mediators and sustained endothelial activation. This results in decreased expression of 
enothelial tight and adherens junction proteins as well as increased cell death culminating 
in elevated vascular permeability in all organs including brain. 
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